GlassScriptPhysician profile
Traci D Morrison
NPI 1245593136
$4,344.36
in general payments reported to CMS, 2019-2025
46 companies · $771 in 2025
The $771 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $743 · 2022: $1,079 · 2023: $817 · 2024: $934 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,521.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $718.33 | 2021-2025 | |
| Pfizer INC. | $321.36 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $280.96 | 2021-2025 | Opdivo, Opdualag, Augtyro |
| Seagen INC. | $246.71 | 2021-2023 | Tukysa, Adcetris |
| Janssen Biotech, INC. | $203.67 | 2022-2024 | Imbruvica, Carvykti, Tecvayli |
| Array Biopharma INC | $173.48 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Merck Sharp & Dohme LLC | $166.39 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Deciphera Pharmaceuticals INC. | $155.90 | 2021-2025 | Qinlock, Romvimza |
| Pharmacyclics LLC, An Abbvie Company | $154.05 | 2021-2023 | Imbruvica |
| Celgene Corporation | $130.26 | 2022-2025 | Reblozyl |
| Abbvie INC. | $113.10 | 2024-2025 | |
| Genzyme Corporation | $111.96 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $104.40 | 2021-2025 | Onivyde, Somatuline Depot |
| Astrazeneca Pharmaceuticals LP | $91.40 | 2021-2025 | Imfinzi |
| Glaxosmithkline, LLC. | $90.93 | 2021-2025 | Ojjaara, Jemperli, Blenrep |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $77.67 | 2021-2023 | Pemazyre, Monjuvi |
| Amgen INC. | $66.30 | 2021-2022 | |
| Blueprint Medicines Corporation | $66.10 | 2022-2023 | Ayvakit |
| Puma Biotechnology, INC. | $64.81 | 2021-2024 | |
| Daiichi Sankyo INC. | $64.00 | 2023-2024 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $63.95 | 2022-2025 | Fruzaqla |
| Karyopharm Therapeutics INC. | $63.00 | 2022-2025 | Xpovio |
| Stemline Therapeutics INC. | $61.28 | 2024 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $56.90 | 2021-2024 | Libtayo |
| Progenics Pharmaceuticals, INC. | $52.79 | 2021-2025 | |
| Exelixis INC. | $51.04 | 2021-2024 | Cabometyx |
| Lilly USA, LLC | $49.91 | 2021-2024 | Jaypirca, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $49.82 | 2021-2024 | |
| Emd Serono, INC. | $48.89 | 2021-2024 | Bavencio |
| Genentech USA, INC. | $43.56 | 2024-2025 | Polivy, Venclexta |
| Aveo Pharmaceuticals, INC. | $42.34 | 2022-2025 | |
| Gilead Sciences, INC. | $41.99 | 2022-2023 | Trodelvy |
| Servier Pharmaceuticals LLC | $36.32 | 2024-2025 | |
| Adc Therapeutics America, INC. | $35.42 | 2021-2022 | |
| Acrotech Biopharma INC. | $31.13 | 2022 | |
| Tersera Therapeutics LLC | $27.00 | 2025 | Quzyttir |
| Rigel Pharmaceuticals, INC. | $25.24 | 2022-2023 | Rezlidhia, Tavalisse |
| Eusa Pharma (US) LLC | $23.41 | 2021 | |
| Kyowa Kirin, INC. | $20.48 | 2025 | |
| Coherus Oncology, INC. | $19.59 | 2025 | Loqtorzi |
| Eisai INC. | $17.70 | 2022 | |
| Myriad Genetic Laboratories, INC. | $17.45 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.01 | 2024 | Xarelto |
| Myovant Sciences INC. | $16.37 | 2022 | |
| Beone Medicines USA, INC. | $15.38 | 2025 | Tevimbra |
| Geron Corporation | $14.61 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traci Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.